Cargando…
Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359667/ https://www.ncbi.nlm.nih.gov/pubmed/37464865 http://dx.doi.org/10.1177/10732748231190122 |
Ejemplares similares
-
Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
por: Zheng, Yanqing, et al.
Publicado: (2021) -
Retracted: FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Healthcare Engineering, Journal of
Publicado: (2023) -
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021) -
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022) -
Retracted: Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)